Intercept off premarket

Shares of Intercept Pharmaceuticals (ICPT) are off 12% premarket on mediocre volume in apparent response The Street's article stating the company's liver disease drug, obeticholic acid (OCA), may cause significant lipid abnormalities, an observation made from its Phase 3 clinical trial evaluating the drug in patients with nonalcoholic steatohepatitis (NASH). Intercept executives appear to have made the decision to downplay the potential negative ramifications of the lipid effects according to a series of January 2014 emails exchanged between the company and a division of NIH.

When the news broke on January 9 about the early stoppage of the trial because of the "highly statistically significant improvement" in the livers of NASH patients treated with OCA versus placebo, the stock rocketed from $72 to $445. Nothing was disclosed about OCA's lipid effects and its role in the decision to stop the trial.

Intercept's market cap is $5.5B so there may be a good-sized haircut for longs awaiting if OCA's potential deleterious lipid effects are confirmed.

From other sites
Comments (3)
  • Holthusen
    , contributor
    Comments (701) | Send Message
    This has been know for months. 56% of the patient population were Type 2 diabetic in the trials, that's why there was lipid abnormalities. If you have a failing Liver are you going to worry about lipid abnormalities that can be treated by other drugs already on the market?
    20 May 2014, 08:50 AM Reply Like
  • BarkingKat
    , contributor
    Comments (3) | Send Message
    Ditto! My grandparents suffered from diabetes and those lipid abnormalities are a part of that disease. And yeah, if I'm in a terminal situation with liver failure I'm NOT going to worry about my lipid profile as we can treat that effectively just as you said.
    I've been closely associated with biotech, medical, etc. having been previously married to a molecular biologist. Also, Experiencing an MTBI several years ago resulted in my in-depth pursuit of whole-body health & wellness starting with the brain and continuing on from there. Given the choice while in liver failure: I'm taking the ICPT route and will deal with side effects while I bring my liver back to normal
    20 May 2014, 10:57 AM Reply Like
  • Mooogli
    , contributor
    Comments (4) | Send Message
    Intercept Safety problems may benefit to the french GENFIT ( company, the only other one to lead a Phase IIb survey finishing Dec. 2014, with a very powerful and SAFE drug against NASH (GFT505).


    And this company is veery underrated now ...


    HTH ;-)
    20 May 2014, 09:10 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs